Annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer
Author:
Funder
Oklahoma Center for the Advancement of Science and Technology
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1186/s43556-023-00167-7.pdf
Reference5 articles.
1. Woodward A, Faria GNF, Harrison RG. Annexin A5 as a targeting agent for cancer treatment. Cancer Lett. 2022;547:215857. https://doi.org/10.1016/j.canlet.2022.215857.
2. Chang W, Fa H, Xiao D, Wang J. Targeting phosphatidylserine for cancer therapy: prospects and challenges. Theranostics. 2020;10:9214–29. https://doi.org/10.7150/thno.45125.
3. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CPM. Extracellular annexin A5: Functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta. 2008;1783:953–63. https://doi.org/10.1016/j.bbamcr.2008.01.030.
4. Bauzon M, Drake PM, Barfield RM, Cornali BM, Rupniewski I, Rabuka D. Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. OncoImmunology. 2019;8:e1565859. https://doi.org/10.1080/2162402X.2019.1565859.
5. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015;7:315ra188. https://doi.org/10.1200/PO.22.00414.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Correction: annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer;Molecular Biomedicine;2024-04-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3